Preferred Stock OfferingsBy Preferred Stock Channel Staff, updated Sun, December 5, 5:25 AM
|This Slide: #56 of 573|
Slide #56. VistaGen Therapeutics, Inc. — Preferred Stock Offering
VistaGen Therapeutics, Inc. (NASDAQ:VTGN)
Date of Pricing:
Price Per Share:
Preferred Stock Offering Details:
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that it commenced an underwritten public offering of units consisting of its common stock, par value $0.001 per share (the "Common Stock"), and its Series D convertible preferred stock (the "Series D Preferred Stock"). All securities to be sold in the offering are to be sold by VistaGen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 12/18- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the "Common Stock"), and 2,000,000 shares of its Series D convertible preferred stock ("Series D Preferred Stock") at a public offering price of $21.16 per share.
VistaGen Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for anxiety, depression and certain additional central nervous system disorders. Co.'s product candidates include: PH94B, which is a neuroactive nasal spray with therapeutic potential in a range of indications involving anxiety or phobia; PH10, which is a synthetic neurosteroid delivered intranasally that has therapeutic potential in a range of neuropsychiatric indications involving depression; and AV-101 (4-Cl-KYN), which is an oral prodrug that targets the N-methyl-D-aspartate receptor, an ionotropic glutamate receptor in the brain.
Open the VTGN Page at Preferred Stock Channel »
Free VTGN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Strong Buy (4.00 out of 4)
(ranked higher than approx. 74% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com